Anti-PD-1 antibodies, a novel treatment option for advanced chemoresistant pulmonary lymphoepithelioma carcinoma

BACKGROUND: Pulmonary lymphoepithelioma-like carcinoma (LELC) exhibits a unique immune microenvironment, including high PD-L1 expression and abundant infiltrating-immune cells. However, the availability of PD-1/PD-L1 inhibitors in patients with LELC is still not determined. METHODS: A total of 36 ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Na, Tang, Hui, Yu, Shuangni, Lin, Yi, Wang, Yingyi, Wang, Yuzhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763302/
https://www.ncbi.nlm.nih.gov/pubmed/36561745
http://dx.doi.org/10.3389/fimmu.2022.1001414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763302/
https://www.ncbi.nlm.nih.gov/pubmed/36561745
http://dx.doi.org/10.3389/fimmu.2022.1001414

Ejemplares similares